TCS: Relief Rally, Not Triumph
TCS reported Q1 FY27 net profit of ₹13,349 crore, up 5% year-on-year, with dollar revenue of $7.62 billion — up a mere 0.04% sequentially and 2.7% annually. Crucially, the actual print beat the Bloomberg consensus of $7.52 billion polled across 34 analysts, meaning the results surprised relative to a deeply pessimistic bar rather than signalling a genuine demand inflection. Management commentary flagged no let-up in client caution, and margin contraction was evident, raising questions about whether the beat reflects operational strength or simply the depth of prior expectations being reset too low.
IT Sector: AI Promise, Structural Doubt
The TCS earnings crystallise a central tension for India's largest IT sector: AI revenues are growing but remain a small fraction of total earnings, while the broader enterprise spending environment stays subdued amid macroeconomic and geopolitical uncertainty. NIFTY IT closed at 27,471.25, down 0.30%, even as broader markets recovered — a divergence that reflects investor scepticism about near-term IT demand recovery. The sector's next leg of re-rating, analysts note, hinges on whether AI deal conversions can materially move the revenue needle within the next two to three quarters.
Markets Recover; Banks Lead Charge
Indian markets staged a meaningful recovery from Wednesday's sharp selloff, with the Sensex closing at 76,741.82 (+0.31%) and the Nifty 50 at 23,962.80 (+0.34%), while investors collectively recovered over ₹5 lakh crore in market capitalisation in a single session. Bank Nifty was the standout performer, rising 0.90% to 57,252.45, reflecting renewed confidence in the financial sector even as HDFC Bank's Q1 results — scheduled for July 18 — remain a critical near-term catalyst. Advancing stocks outnumbered decliners by more than two to one, and the broader midcap and smallcap indices outperformed, suggesting the recovery was not narrowly concentrated.
Jewellery Shines, Pharma Stumbles
Kalyan Jewellers was the session's marquee performer, hitting a 10% upper circuit at ₹411.75 for the second consecutive session after reporting an estimated 38% year-on-year surge in Q1 FY27 consolidated revenue, driven by strong domestic and international demand, new showroom launches, and traction in its digital platform Candere. In sharp contrast, Dr. Reddy's Laboratories fell approximately 7% after the company disclosed a delay in commercial semaglutide supplies due to a quality issue with the active pharmaceutical ingredient — a significant setback given the high strategic importance of the GLP-1 weight-loss drug space. The pharma sector's internal divergence was stark: while Dr. Reddy's dragged sentiment, the broader index found support from realty and mid-cap names.
EMS Sector Gets Policy Tailwind
Electronics Manufacturing Services stocks rallied sharply after the government extended customs duty concessions on machinery for lithium-ion battery and display component manufacturing, reinforcing policy commitment to India's domestic electronics ecosystem. Syrma SGS Technology and Dixon Technologies were flagged as strong performers, with sector peers like Kaynes Technology also posting gains of up to 7.5% following the announcement that basic customs duty waivers on key electronic components will run through 2029. This policy continuity reduces cost uncertainty for EMS players investing in capacity expansion and aligns with India's broader ambition to become a global electronics manufacturing hub.
Iran-US Tensions Keep Oil Elevated
Fresh U.S. military strikes against Iran pushed Brent crude futures to $78.8 a barrel intraday — nearing the psychologically significant $80 level — even as the market data snapshot shows Brent at $76.29 (-0.01%) at the time of this briefing, reflecting some intraday volatility. The Strait of Hormuz remains a focal point: shipowners are adopting more cautious routing, and insurance providers are reviewing policy terms following recent vessel attacks. For India, which imports over 85% of its crude requirements, sustained oil above $80 per barrel would compound the ADB's recently revised concern that elevated energy costs are already squeezing household purchasing power and were a key reason for cutting India's FY27 GDP forecast to 6.6%.
IPO Pipeline Accelerates
SBI Funds Management — India's largest AMC — has set its IPO price band at ₹545–574 per share, aiming to raise ₹11,693–11,962 crore in what is already the largest public issue of 2026, opening July 14. The offering is structured as an offer for sale, meaning existing shareholders SBI and Amundi are monetising stakes rather than the company raising fresh capital — a distinction that matters when assessing how proceeds benefit the underlying business. Meanwhile, Kusumgar's IPO crossed 12x subscription on Day 2, with the NII category leading at 36x, pointing to robust appetite in the primary market even as secondary markets remain volatile.
FIIs Return; Macro Risks Linger
Foreign institutional investors were net buyers of Indian equities for the sixth consecutive session, a meaningful shift after a $60 billion exodus since September 2024, with improving macros and relatively attractive valuations cited as potential drivers of sentiment stabilisation. However, the ADB's downward revision of India's FY27 growth forecast to 6.6% — citing higher energy costs, rising inflation projected at 5.2% for FY27, and geopolitical risks — provides a more cautious macro backdrop. Monsoon distribution remains uneven despite the headline deficit narrowing to 15%, with nearly 100 rain-fed districts experiencing moisture stress that economists warn could translate into higher kharif crop losses and food inflation pressures.